that only 10% of the world's population was covered by any one of the measures, and identified wide variation in the implementation of mpower measures within Africa. (4) Physicians can make contributions to all aspects of tobacco control, for example through advocacy, policy development, political engagement and role modelling. But for most doctors, the most direct opportunity to reduce smoking will be in the clinical setting, through encouraging individuals to stop smoking and developing services to support them in doing so. My objective here is to review the evidence for the effectiveness of smoking cessation interventions available to the physician advising patients how to stop smoking. The available interventions include behavioural interventions (brief advice, self-help materials, counselling), complementary therapies (hypnotherapy and acupuncture) and pharmacological therapy (nicotine replacement, antidepressants and the nicotine partial receptor agonist Varenicline).
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Volume 8 • Number 1 Cochrane Tobacco Addiction Review Group maintains a register of controlled trials in smoking cessation. Systematic reviews based on this register are published in the Cochrane Library, and are regularly updated. Detailed bibliographies of the included trials can be found within each review.
The aim of these reviews is to identify and synthesise the most reliable evidence evaluating interventions for smoking cessation.
For individual patient interventions, the most reliable evidence comes from randomised controlled trials. In the Cochrane reviews, the principal outcome is sustained smoking cessation, defined as being at least six months after the intervention. Where appropriate, meta-analyses of individual trials provide a summary estimate of the effect of the interventions tested. This pooled estimate is expressed as a relative risk with 95% confidence intervals, where a relative risk greater than one indicates a higher likelihood of abstinence.
AdVIce froM A doctor
Physician advice to quit smoking is an inexpensive intervention, which can be offered in most healthcare settings. A Cochrane review of physician advice identified 41 trials, conducted between 1972 and 2007, including over 31 000 participants. (5) The most common setting for delivery of advice was primary care, but there were also studies in hospital wards, outpatient clinics, and workplace clinics. Meta-analysis of 17 trials of brief advice versus no advice (or usual care) detected a significant increase in the rate of quitting (relative risk [RR] 1.66; 95% confidence interval [CI]
1.42 to 1.94). There is little evidence as to whether giving the advice in different ways is more or less effective, though there is a small additional benefit from spending more time with the patient: Amongst 11 trials of more intensive advice the estimated effect was higher (RR 1.84; 95% CI 1.60 to 2.13) but there was no statistical difference between the intensive and minimal subgroups. Direct comparison of intensive versus minimal advice showed a small advantage of intensive advice (RR 1.37; 95% CI 1.20 to 1.56), and this effect may be greater in patients with medical conditions related to smoking, such as cardiac and respiratory disease, than in apparently healthy smokers. There was insufficient evidence to draw any conclusion about the effect of motivational as opposed to simple advice or between different advice-giving styles.
self-help MAterIAls
Self-help materials in various formats are a low cost option for supporting smoking cessation, but their effectiveness is low. In 12 trials involving 15 711 participants that compared self-help materials to no intervention, a Cochrane review (search date 2008) found a pooled effect that just reached statistical significance (RR 1.21; 95% CI 1.05 to 1.39). (6) The review did not detect a benefit from adding self-help materials to brief advice, or to nicotine replacement therapy. There were 25 trials using materials tailored for the characteristics of individual smokers, where meta-analysis supported a small benefit of tailored materials (RR 1.31; 95% CI 1.20 to 1.42). The evidence is strongest for tailored materials compared to no intervention, but also supports tailored materials as more helpful than standard materials. Part of this effect could be due to the additional contact or assessment required to obtain individual data.
counsellIng
Counselling can be provided to those seeking to quit smoking either through face to face contact with an individual healthcare worker or in group settings. A Cochrane review of individual counselling identified 30 trials with over 7 000 participants. (7) It found that individual counselling was more effective than a minimal intervention, with a relative risk for smoking cessation at longterm follow up of 1.39, 95% CI 1.24 to 1.57. Counselling provided additional benefit in patients receiving NRT. The review was unable to detect whether any specific form of counselling was more effective than another. A Cochrane review of group counselling (search date 2008) found similar effects in the group setting, but poor attendance at group counselling limits the usefulness of this approach. (8) Face to face intervention may not be crucial to the success of counselling. A Cochrane review of telephone counselling (search date 2008) found that both proactive and reactive quit lines improve quit rates to a similar degree. (9) nIcotIne replAceMent therApy Nicotine replacement therapy (NRT) aims to aid smoking cessation by providing nicotine to reduce withdrawal symptoms and craving. It is appropriate for patients who show evidence of nicotine dependence, usually those who smoke more heavily, start early in the day and have withdrawals symptoms when they stop smoking. Nicotine is available as transdermal patches, chewing gum, nasal spray, as an inhaler and as sublingual lozenges. A Cochrane review of NRT (search date 2007) identified 132 trials. (10) Within these trials over 40 000 participants contributed to the primary comparison between any type of NRT and a placebo or non-NRT control group. The RR of abstinence for any form of NRT relative to control was 1.58 (95% CI 1.50 to 1.66). There were no significant differences between the effects obtained using different nicotine products. The effects were largely independent of the duration of therapy, the intensity of additional support provided, or the setting in which the NRT was offered. There was some evidence of a small benefit from combining the nicotine patch with a form allowing ad lib dosing compared to use of a single form. Use of combination therapy may be considered for patients who have been unable to quit using a single type of NRT. There was borderline evidence that there is a small benefit from use of the nicotine patch at doses higher than 22mg (24 hours), or 15mg (16 hours) compared to the standard dose patch. Use of these may be considered for heavy smokers (i.e. smoking 30 or more cigarettes a day), or for patients relapsing because of persistent craving and withdrawal symptoms on standard dose therapy. There is limited evidence that a repeated course of NRT in patients who have relapsed after recent use of nicotine patches, will result in a small additional probability of quitting. One study directly compared NRT with Bupropin. Quit rates with Bupropion were higher than with nicotine patch or placebo. (11) Although there is an additional benefit when NRT is combined with behavioural support, NRT increases cessation rates whether behavioural support is provided or not, so it is still worth suggesting NRT if the resources are not available to provide such support.
AntIdepressAnts
There is increasing evidence that some antidepressants help Bupropion has been associated with suicide risk, but whether this is causal is unclear. Nortriptyline has the potential for serious side-effects, but none have been seen in the few small trials for smoking cessation. 
coMpleMentAry therApIes
Hypnotherapy and acupuncture continue to be used as smoking cessation interventions. There are methodological difficulties in conducting high quality trials of these interventions. The Cochrane reviews failed to detect a specific effect of either hypnotherapy or acupuncture on smoking cessation, but practitioner attention may provide a non-specific effect comparable to counselling. (14, 15) dIscussIon This review shows that there is evidence that a range of inter- Individuals taking up pharmacological treatment for smoking cessation are likely to be more motivated than the general population of smokers, so their unassisted quit rate may be assumed to be higher when calculating NNT's. Based on a median no-treatment (placebo) clinical trial quit rate of 7.5% the NNT for NRT is 23 (95% CI 20 to 27), for Bupropion 18 (95% CI 14 to 23), and for Varenicline 10 (95% CI 7 to 14). These numbers compare favourably with other preventive healthcare interventions. (4) The ability of physicians to help their patients to quit smoking will of course vary depending on the resources available within their country and locality. In South Africa, Varenicline is not yet available, although it is likely that it will be licensed in the near future.
As a measure of provision of treatment for tobacco dependence, the World Health Organisation tracks availability of eight evidencebased treatment resources described in this review: access to a national toll-free quit line, ability to purchase NRT, Bupropion and Varenicline, and smoking cessation support in primary care, in hospitals, in offices of health professionals and in the community.
WHO's 2009 report on the global tobacco epidemic shows wide variation in availability of these resources. The report found that seventeen mainly high-income countries provide comprehensive smoking cessation services encompassing in full or in part all eight of these resources. About a third of middle-income countries and less than 15% of low-income countries provide coverage for NRT and/or cessation services. (4) Only four middle-income countries and no low-income countries provide a national toll-free quit line and coverage for both NRT and cessation services. In the majority of low-and middle-income countries, the cost of cessation assistance is not covered by government, and 8% of middleincome and 29% of low-income countries provide no assistance to smokers. Together with measures to control supply and demand for tobacco, identifying the resources to increase availability of tobacco dependence treatment is a major public health challenge for clinicians and for the global community. 
